MarketCap
Facebook
X
TelegramFluidigm Corporation Total Liabilities 2011-2026 | FLDM
Annual Total Liabilities Fluidigm Corporation
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 186 M | 111 M | 232 M | 256 M | 253 M | 256 M | 257 M | 20.5 M | 13.1 M | 22.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 257 M | 13.1 M | 161 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K |  USA |
 |
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 203.06 | -0.38 % | $ 22.5 B | USA |
 |
Celcuity
CELC
|
366 M | $ 88.55 | -1.05 % | $ 4.14 B | USA |
|
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Co-Diagnostics
CODX
|
4.11 M | $ 4.29 | -8.72 % | $ 5.71 M | USA |
 |
Fulgent Genetics
FLGT
|
107 M | $ 18.68 | -0.53 % | $ 575 M | USA |
 |
Castle Biosciences
CSTL
|
108 M | $ 20.7 | -1.48 % | $ 600 M | USA |
 |
Aspira Women's Health
AWH
|
12.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
84.6 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
ICON Public Limited Company
ICLR
|
7.08 B | $ 146.18 | -2.49 % | $ 11.5 B |  Irlanda |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
2.11 B | $ 131.62 | 0.55 % | $ 16.5 B | USA |
 |
CareDx, Inc
CDNA
|
110 M | $ 22.97 | -2.92 % | $ 1.22 B | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Check-Cap Ltd.
CHEK
|
1.83 M | - | - | $ 9.42 M |  Israel |
 |
Interpace Biosciences
IDXG
|
11.5 M | $ 1.6 | -3.03 % | $ 7.08 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 160.97 | -3.15 % | $ 25 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M |  China |
 |
National Research Corporation
NRC
|
121 M | $ 18.79 | - | $ 421 M | USA |
 |
Natera
NTRA
|
686 M | $ 212.07 | -3.27 % | $ 29 B | USA |
 |
Genetic Technologies Limited
GENE
|
4.36 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
Pacific Biosciences of California
PACB
|
779 M | $ 1.31 | -2.96 % | $ 393 M | USA |
 |
Lantheus Holdings
LNTH
|
1.14 B | $ 104.52 | 0.19 % | $ 7.05 B | USA |
 |
Charles River Laboratories International
CRL
|
3.92 B | $ 187.51 | -0.29 % | $ 9.29 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
Medpace Holdings
MEDP
|
1.52 B | $ 467.34 | -1.63 % | $ 13.5 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.46 B | - | - | $ 19.8 B | USA |
 |
Mettler-Toledo International
MTD
|
3.74 B | $ 1 131.49 | -0.86 % | $ 23.3 B |  Schweiz |
 |
NeoGenomics
NEO
|
523 M | $ 11.15 | -2.79 % | $ 1.43 B | USA |
 |
Myriad Genetics
MYGN
|
339 M | $ 4.33 | -6.48 % | $ 401 M | USA |
 |
Personalis
PSNL
|
73 M | $ 9.59 | 1.8 % | $ 856 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
16 B | $ 26.46 | 1.34 % | $ 25.1 B |  Niderland |
 |
Twist Bioscience Corporation
TWST
|
169 M | $ 76.17 | 2.86 % | $ 4.56 B | USA |
 |
Senseonics Holdings
SENS
|
65.2 M | $ 7.18 | -2.05 % | $ 300 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
114 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.05 | -1.91 % | $ 4.71 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
9.76 B | $ 266.16 | 0.34 % | $ 22.1 B | USA |
 |
Thermo Fisher Scientific
TMO
|
28.7 B | $ 469.34 | -1.33 % | $ 177 B | USA |
 |
Trinity Biotech plc
TRIB
|
138 M | $ 0.65 | -3.7 % | $ 233 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Neogen Corporation
NEOG
|
1.37 B | $ 9.1 | -1.57 % | $ 1.97 B | USA |
 |
Invitae Corporation
NVTA
|
1.85 B | - | - | $ 21.2 M | USA |